<?xml version="1.0" encoding="UTF-8"?>
<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia was first noted in Wuhan (China) in December 2019
 <sup>
  <xref rid="R1" ref-type="bibr">1</xref>
 </sup> and the disease induced by the virus has been termed coronavirus infectious disease 2019 (COVID-19). To date, various treatment regimens are being evaluated as potential tools in COVID-19 in addition to the standard supportive care including oxygen supply, intensive care admission, or even extracorporeal membrane oxygenation for critically ill patients.
 <sup>
  <xref rid="R2" ref-type="bibr">2</xref>
 </sup> Among agents, antiviral drugs such as remdesivir,
 <sup>
  <xref rid="R3" ref-type="bibr">3</xref>
 </sup> lopinavir/ritonavir,
 <sup>
  <xref rid="R4" ref-type="bibr">4</xref>
 </sup> the antimalarial agent hydroxychloroquine in combination with azithromycin,
 <sup>
  <xref rid="R5" ref-type="bibr">5</xref>
 </sup> and monoclonal antibodies, such the anti-interleukin-6 receptor tocilizumab,
 <sup>
  <xref rid="R6" ref-type="bibr">6</xref>â€“
  <xref rid="R8" ref-type="bibr">8</xref>
 </sup> are currently under evaluation for treatment of COVID-19.
</p>
